Amod Sarnaik, MD, reviews data from a study presented at The Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting on lifileucel tumor-infiltrating lymphocyte [TIL] monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapy.
Clinical Trials
Melanoma With Confirmed Progression: Effect of Lenvatinib Plus Pembrolizumab
The following is a summary of “Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination,” published in the January 2023 issue of Oncology by Arance, et al.
Woman presents with right eye redness, shadow in vision
A 59-year-old woman who presented to an outside eye care provider 1 year prior for right eye redness and a shadow in her vision was referred to the New England Eye Center when the redness did not respond to eye drops.
Oncolytic Virus/Immunotherapy Combination Delivers Early Survival Benefit in Melanoma
The preliminary efficacy and tolerability observed with vusolimogene oderparepvec (RP1) plus nivolumab (Opdivo) in patients with cutaneous melanoma signal the expansion of the use of oncolytic viruses to manage cancers that are resistant to PD-1 inhibition, according to Bartosz Chmielowski, MD.